ArticleNature communications2018
Author Correction: Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia.
Abstract readPublished Erratum
In one paragraph
Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Prognostic Model of Seven Immune Genes to Predict Overall Survival in Childhood Acute Myeloid Leukemia.BioMed research international · 2022Article
Corrections and comments
- Erratum for
Authors and funding
34 authors.
Xi JiangDepartment of Cancer Biology, University of Cincinnati, Cincinnati, OH, 45219, USA. xjiang@coh.org.
Chao HuDepartment of Cancer Biology, University of Cincinnati, Cincinnati, OH, 45219, USA.
Kyle FerchenDepartment of Cancer Biology, University of Cincinnati, Cincinnati, OH, 45219, USA.
Ji NieDepartment of Chemistry, Department of Biochemistry and Molecular Biology, Institute for Biophysical Dynamics, Howard Hughes Medical Institute, University of Chicago, Chicago, IL, 60637, USA.
Xiaolong CuiDepartment of Chemistry, Department of Biochemistry and Molecular Biology, Institute for Biophysical Dynamics, Howard Hughes Medical Institute, University of Chicago, Chicago, IL, 60637, USA.
Chih-Hong ChenDepartment of Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, CA, 91010, USA.
Liting ChengKey Laboratory of Luminescence and Real-time Analytical Chemistry (Ministry of Education), College of Pharmaceutical Sciences, Southwest University, Chongqing, 400715, China.
Zhixiang ZuoDepartment of Cancer Biology, University of Cincinnati, Cincinnati, OH, 45219, USA.
William SeibelDivision of Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 45229, USA.
Chunjiang HeSchool of Basic Medical Sciences, Wuhan University, Wuhan, 430071, China.
Yixuan TangKey Laboratory of Luminescence and Real-time Analytical Chemistry (Ministry of Education), College of Pharmaceutical Sciences, Southwest University, Chongqing, 400715, China.
Jennifer R SkibbeDepartment of Cancer Biology, University of Cincinnati, Cincinnati, OH, 45219, USA.
Mark WunderlichExperimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 45229, USA.
William C ReinholdDevelopmental Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD, 20892, USA.
Lei DongDepartment of Cancer Biology, University of Cincinnati, Cincinnati, OH, 45219, USA.
Chao ShenDepartment of Cancer Biology, University of Cincinnati, Cincinnati, OH, 45219, USA.
Stephen ArnovitzSection of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, 60637, USA.
Bryan UlrichSection of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, 60637, USA.
Jiuwei LuDepartment of Cancer Biology, University of Cincinnati, Cincinnati, OH, 45219, USA.
Hengyou WengDepartment of Cancer Biology, University of Cincinnati, Cincinnati, OH, 45219, USA.
Rui SuDepartment of Cancer Biology, University of Cincinnati, Cincinnati, OH, 45219, USA.
Huilin HuangDepartment of Cancer Biology, University of Cincinnati, Cincinnati, OH, 45219, USA.
Yungui WangDepartment of Cancer Biology, University of Cincinnati, Cincinnati, OH, 45219, USA.
Chenying LiDepartment of Cancer Biology, University of Cincinnati, Cincinnati, OH, 45219, USA.
Xi QinDepartment of Cancer Biology, University of Cincinnati, Cincinnati, OH, 45219, USA.
James C MulloyExperimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 45229, USA.
Yi ZhengExperimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 45229, USA.
Jiajie DiaoDepartment of Cancer Biology, University of Cincinnati, Cincinnati, OH, 45219, USA.ORCID http://orcid.org/0000-0003-4288-3203
Jie JinDepartment of Hematology, The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, 310003, China.
Chong LiKey Laboratory of Luminescence and Real-time Analytical Chemistry (Ministry of Education), College of Pharmaceutical Sciences, Southwest University, Chongqing, 400715, China.
Paul P LiuGenetics and Molecular Biology Branch, National Human Genome Research Institute, NIH, Bethesda, MD, 20892, USA.
Chuan HeDepartment of Chemistry, Department of Biochemistry and Molecular Biology, Institute for Biophysical Dynamics, Howard Hughes Medical Institute, University of Chicago, Chicago, IL, 60637, USA.
Yuan ChenDepartment of Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, CA, 91010, USA.
Jianjun ChenDepartment of Cancer Biology, University of Cincinnati, Cincinnati, OH, 45219, USA. jianchen@coh.org.
Funding
SUMO modification and DNA damage response in cancer therapyR01GM086171 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHEN, YUAN · 2008 to 2020
$5.2MTargeting c-Myc and Proteasome Inhibitor Resistance in Multiple MyelomaR01CA212119 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHEN, YUAN · 2017 to 2021
$2.8MThe role and mechanism of METTL3/METTL14-mediated RNA modification in the pathogenesis and drug-resistance of AMLR01CA236399 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI CHEN, JIANJUN · 2019 to 2023
$2.3MTargeting TET1 signaling to treat acute myeloid leukemiaR01CA211614 · NCI · UNIVERSITY OF CINCINNATI · PI CHEN, JIANJUN · 2017 to 2021
$2.3MThe role and mechanism of FTO in leukemogenesis and drug responseR01CA214965 · NCI · UNIVERSITY OF CINCINNATI · PI CHEN, JIANJUN · 2017 to 2021
$2.1MTherapeutic insights through patient derived leukemia xenograftsR50CA211404 · NCI · CINCINNATI CHILDRENS HOSP MED CTR · PI Mark Wunderlich · 2016 to 2026
$1.9MPotential therapeutic implications of targeting miR-150 in acute myeloid leukemiaR01CA182528 · NCI · UNIVERSITY OF CINCINNATI · PI CHEN, JIANJUN · 2014 to 2018
$1.7MThe role and functional mechanism of TET1 in MLL-rearranged leukemiaR01CA178454 · NCI · UNIVERSITY OF CINCINNATI · PI CHEN, JIANJUN · 2014 to 2018
$1.7MThe role and functional mechanism of a miRNA cluster, mir-17-92 in leukemogenesisR01CA127277 · NCI · UNIVERSITY OF CHICAGO · PI CHEN, JIANJUN · 2008 to 2012
$1.4MComparison of molecular factors to drug activities.ZICBC011509 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI REINHOLD, WILLIAM · 2013 to 2025
$1.4MNCI NIH HHS R01 CA127277NCI NIH HHS R01 CA178454NCI NIH HHS R01 CA182528NCI NIH HHS R01 CA211614NCI NIH HHS R01 CA212119NCI NIH HHS R01 CA214965NCI NIH HHS R01 CA236399NCI NIH HHS R50 CA211404NIGMS NIH HHS R01 GM086171
Abstract
The original version of this Article contained an error in the spelling of the author James C. Mulloy, which was incorrectly given as James Mulloy. This has now been corrected in both the PDF and HTML versions of the Article.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.